1.645

2.65% -0.055

Milestone Pharmaceuticals Inc (MIST)

Overview News Price History Option Chain Financials Discussions Forecast

Milestone Pharmaceuticals Inc stock is traded at $1.645, with a volume of 105.79K. It is down -2.65% in the last 24 hours and down -1.49% over the past month. Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Previous Close:

$1.70

Open:

$1.69

24h Volume:

105.79K

Relative Volume:

0.02

Market Cap:

$139.90M

Revenue:

$1,000.00K

Net Income/Loss:

$-58.01M

P/E Ratio:

-1.9046

EPS:

-0.8637

Net Cash Flow:

$-43.20M

1W Performance:

-5.43%

1M Performance:

-1.49%

6M Performance:

-13.80%

1Y Performance:

-16.83%

1-Day Range:

$1.64

$1.69

1-Week Range:

$1.65

$1.79

52-Week Range:

$0.6254

$3.06

Milestone Pharmaceuticals Inc Stock (MIST) Company Profile

Name

Milestone Pharmaceuticals Inc

Sector

Healthcare (1121)

Industry

Biotechnology (620)

Phone

(514) 336-0444

Address

1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC

Employee

Twitter

@MilestonePharma

Next Earnings Date

2026-03-20

Latest SEC Filings

MIST's Discussions on Twitter

Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIST Milestone Pharmaceuticals Inc	1.6426	144.79M	1,000.00K	-58.01M	-43.20M	-0.8637
VRTX Vertex Pharmaceuticals Inc	452.64	114.72B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	741.21	78.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	684.13	42.38B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	312.94	41.75B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	282.26	31.33B	5.36B	287.73M	924.18M	2.5229

Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-25	Upgrade	TD Cowen	Hold → Buy
Sep-11-25	Initiated	Wells Fargo	Overweight
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Jun-20-23	Downgrade	Jefferies	Buy → Hold
Apr-22-22	Upgrade	Piper Sandler	Neutral → Overweight
Mar-05-21	Initiated	H.C. Wainwright	Buy
Jul-29-20	Upgrade	Oppenheimer	Perform → Outperform
Jul-24-20	Upgrade	Jefferies	Hold → Buy
Mar-25-20	Downgrade	Jefferies	Buy → Hold
Mar-24-20	Downgrade	Oppenheimer	Outperform → Perform
Mar-24-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-04-19	Initiated	Oppenheimer	Outperform
Jun-03-19	Initiated	Cowen	Outperform
Jun-03-19	Initiated	Jefferies	Buy
Jun-03-19	Initiated	Piper Jaffray	Overweight

View All

Milestone Pharmaceuticals Inc Stock (MIST) Latest News

Mar 18, 2026

Investment Review: Should I invest in Milestone Pharmaceuticals Inc before earningsQuarterly Profit Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn

Mar 18, 2026

Mar 16, 2026

Milestone Pharmaceuticals (MIST) Highlights Etripamil's Safety a - GuruFocus

Mar 16, 2026

Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - Bitget

Mar 16, 2026

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times

Mar 16, 2026

FDA-approved PSVT nasal spray shows minimal blood pressure change - Stock Titan

Mar 16, 2026

Mar 15, 2026

Boxer Capital Management LLC Invests $1.33 Million in Milestone Pharmaceuticals Inc. $MIST - MarketBeat

Mar 15, 2026

Mar 14, 2026

Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality - Seeking Alpha

Mar 14, 2026

Mar 13, 2026

MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill

Mar 13, 2026

Mar 12, 2026

Milestone Pharmaceuticals Sets March 20 Call for 2025 Results and Business Update - TipRanks

Mar 12, 2026

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - Bitget

Mar 12, 2026

Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan

Mar 12, 2026

Mar 11, 2026

Swing Trade: What is the long term forecast for Milestone Pharmaceuticals Inc stockWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn

Mar 11, 2026

Wells Fargo Initiates Coverage of Milestone Pharmaceuticals (MIST) with Overweight Recommendation - MSN

Mar 11, 2026

Mar 09, 2026

Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Mar 09, 2026

Mar 08, 2026

Stock Report: Does Milestone Pharmaceuticals Inc have consistent dividend growthRecession Risk & Safe Entry Point Alerts - baoquankhu1.vn

Mar 08, 2026

Mar 06, 2026

Earnings Report: Should I invest in Milestone Pharmaceuticals Inc before earningsShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn

Mar 06, 2026

Mar 05, 2026

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - MSN

Mar 05, 2026